18-MC: The New Hope in Addiction Treatment?
If this drug works in 2/3 of people, which I think it might, that's a big step forward. - Ron Glick
Imagine a drug that offers the benefits of addiction therapy without the hallucinogenic side effects. In this episode of Elevation Recovery, hosts Chris Scott and Matt Finch dive into the promising world of 18-MC, a manmade derivative of ibogaine. Unlike its parent compound, 18-MC eliminates the hallucinogenic effects while retaining the therapeutic benefits, making it a potential game-changer in addiction treatment.
The hosts discuss how MindMed, a Silicon Valley startup, has acquired 18-MC and is spearheading human trials to gain FDA approval. They explore the history of ibogaine in treating opioid withdrawal and other addictions, and why 18-MC could be a safer alternative. The episode features insights from Ron Glick, an expert in addiction treatment, who shares his perspective on how 18-MC could impact the future of recovery.
Throughout the conversation, Chris and Matt emphasize the importance of scientific research and real-world evidence in validating new treatments. They also touch on the broader landscape of psychedelic therapy and its limitations. If you're curious about innovative approaches to addiction recovery or looking for the latest breakthroughs, this episode is packed with valuable information and thoughtful discussion.
Tune in to Elevation Recovery for an engaging and informative look at how 18-MC might just be the breakthrough we've been waiting for in addiction treatment.